157 related articles for article (PubMed ID: 11131218)
1. Use of danaparoid sodium (Orgaran) as an alternative to heparin sodium during cardiopulmonary bypass: a clinical evaluation of six cases.
Fernandes P; Mayer R; MacDonald JL; Cleland AG; Hay-McKay C
Perfusion; 2000 Nov; 15(6):531-9. PubMed ID: 11131218
[TBL] [Abstract][Full Text] [Related]
2. Cardiopulmonary bypass with danaparoid sodium and ancrod in heparin-induced thrombocytopenia.
Kanagasabay RR; Unsworth-White MJ; Robinson G; Bevan D; Farnsworth G; Haxby EJ; Smith EE
Ann Thorac Surg; 1998 Aug; 66(2):567-9. PubMed ID: 9725413
[TBL] [Abstract][Full Text] [Related]
3. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Farner B; Eichler P; Kroll H; Greinacher A
Thromb Haemost; 2001 Jun; 85(6):950-7. PubMed ID: 11434701
[TBL] [Abstract][Full Text] [Related]
4. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium.
Grocott HP; Root J; Berkowitz SD; deBruijn N; Landolfo K
J Cardiothorac Vasc Anesth; 1997 Dec; 11(7):875-7. PubMed ID: 9412888
[No Abstract] [Full Text] [Related]
5. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
6. Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.
Murphy GS; Marymont JH
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):113-26. PubMed ID: 17289495
[No Abstract] [Full Text] [Related]
7. Lifesaving citrate anticoagulation to bridge ineffective danaparoid [correction of to bridge to danaparoid] treatment.
Dworschak M; Hiesmayr JM; Lassnigg A
Ann Thorac Surg; 2002 May; 73(5):1626-7. PubMed ID: 12022563
[TBL] [Abstract][Full Text] [Related]
8. [Current treatment concepts in heparin-induced thrombocytopenia].
Ranze O; Greinacher A
Dtsch Med Wochenschr; 1999 Jul; 124(28-29):865-73. PubMed ID: 10432950
[No Abstract] [Full Text] [Related]
9. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis.
Schmahl KS; Ganjoo AK; Harloff MG
J Cardiothorac Vasc Anesth; 1997 Apr; 11(2):262-3. PubMed ID: 9106004
[No Abstract] [Full Text] [Related]
10. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
11. In vitro cross-reactivity of danaparoid sodium in patients with heparin-induced thrombocytopenia type II undergoing cardiovascular surgery.
Koster A; Meyer O; Hausmann H; Kuppe H; Hetzer R; Mertzlufft F
J Clin Anesth; 2000 Jun; 12(4):324-7. PubMed ID: 10960207
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
13. Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Macchi L; Sarfati R; Guicheteau M; Chamlian V; Pourrat O; Gruel Y; Magnin G; Brizard A; Boinot C
Clin Appl Thromb Hemost; 2000 Oct; 6(4):187-9. PubMed ID: 11030522
[TBL] [Abstract][Full Text] [Related]
14. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).
Saxon BR; Black MD; Edgell D; Noel D; Leaker MT
Ann Thorac Surg; 1999 Sep; 68(3):1076-8. PubMed ID: 10510017
[TBL] [Abstract][Full Text] [Related]
15. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Aouifi A; Blanc P; Piriou V; Bastien OH; Ffrench P; Hanss M; Lehot JJ
Ann Thorac Surg; 2001 Feb; 71(2):678-83. PubMed ID: 11235727
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
17. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II.
Zöhrer' B; Zenz W; Rettenbacher A; Covi P; Kurnik K; Kroll H; Grubbauer HM; Muntean W
Acta Paediatr; 2001 Jul; 90(7):765-71. PubMed ID: 11519979
[TBL] [Abstract][Full Text] [Related]
18. A comparative review of the adverse effect profiles of heparins and heparinoids.
Borris LC; Lassen MR
Drug Saf; 1995 Jan; 12(1):26-31. PubMed ID: 7537967
[TBL] [Abstract][Full Text] [Related]
19. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
Gitlin SD; Deeb GM; Yann C; Schmaier AH
J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study.
Chong BH; Gallus AS; Cade JF; Magnani H; Manoharan A; Oldmeadow M; Arthur C; Rickard K; Gallo J; Lloyd J; Seshadri P; Chesterman CN;
Thromb Haemost; 2001 Nov; 86(5):1170-5. PubMed ID: 11816702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
